BAY 418543

Drug Profile

BAY 418543

Alternative Names: BAY 41-8543

Latest Information Update: 06 Oct 2006

Price : $50

At a glance

  • Originator Bayer
  • Class Small molecules
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Hypertension

Most Recent Events

  • 06 Oct 2006 Discontinued - Preclinical for Hypertension in Germany (unspecified route)
  • 06 Oct 2006 Discontinued - Phase-I for Angina pectoris in Germany (unspecified route)
  • 16 Apr 2002 A preclinical study has been added to the Hypertension pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top